75N93021F00002↗
Battelle Memorial Institute received this contract from National Institutes of Health Niaid, National Institutes of Health: $10.89M obligated so far for health r&d services; health care services; applied research. It runs to 2026-12-31.
Key facts · data as of Oct 28, 2026
- Recipient
- Battelle Memorial Institute
- Awarding agency
- National Institutes of Health (Department of Health and Human Services)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Obligated to date
- $10.89M
- Potential value
- $15.77M
- Ends
- 2026-12-31
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 28, 2026.
Cite this page: SpendQuery, Award 75N93021F00002, data as of Oct 28, 2026, https://spendquery.com/award?id=CONT_AWD_75N93021F00002_7529_75N93018D00013_7529
Battelle Memorial Institute: all federal awards · Department of Health and Human Services: spending · National Institutes of Health Niaid: what it buys · The follow-on: recompete brief
PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES
Up for re-bid: ends 2026-12-31. Recompete brief → · Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases (CRID) ↗
What it is
- Product or service
- Health R&D Services; Health Care Services; Applied Research (PSC AN12)
- Industry
- Research and Development in Nanotechnology (NAICS 541713)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Competition
- Full and open competition
- Pricing
- Cost plus fixed fee
- How it was bought
- Single-award IDIQ · under 75N93018D00013
- Where the work is
- Franklin, OH · district OH-03
- Funding law
- COVID-19 laws
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
8 subawards totaling $4.32M (39.7% of what was obligated), as Battelle Memorial Institute reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| Mriglobal | $1.51M | 2 | MO | 2022-11-23 | 2024-01-23 |
| Amplifybio, LLC | $1.35M | 2 | OH | 2024-08-19 | 2024-09-26 |
| Inotiv, Inc | $927.4K | 1 | IN | 2023-03-10 | 2023-03-10 |
| Fiore Principi Attivi SRL | $475.0K | 2 | PA | 2025-10-14 | 2025-12-24 |
| Zalgen Labs LLC | $54.0K | 1 | MD | 2023-12-12 | 2023-12-12 |
The largest single subawards
| Date | To | Amount | For |
|---|---|---|---|
| 2022-11-23 | Mriglobal | $1.33M | GLP GENERAL SAFETY AND TOXICITY STUDY PROTOCOL DEVELOPMENT |
| 2023-03-10 | Inotiv, Inc | $927.4K | CONDUCT REPRODUCTIVE TOX STUDIES |
| 2024-09-26 | Amplifybio LLC | $722.3K | PROTOCOL DEVELOPMENT AND STUDY EXECUTION |
| 2024-08-19 | Amplifybio LLC | $631.8K | PROTOCOL DEVELOPMENT AND STUDY EXECUTION |
| 2025-10-14 | Frontage Laboratories, Inc | $415.0K | AAHI GLP TOX STUDY |
| 2024-01-23 | Mriglobal | $180.4K | NEXT GENERATION COVID VACCINES |
| 2025-12-24 | Frontage Laboratories, Inc | $60.0K | DEVELOP STUDY PROTOCOL DRAFT |
| 2023-12-12 | Zalgen Labs LLC | $54.0K | ELISA KITS |
Every action
9 actions since 2023-06-20. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2025-12-18 | P00010 | Supplemental agreement (work within scope) | $0 | PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES |
| 2025-09-24 | P00009 | Supplemental agreement (work within scope) | $335.0K | PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES |
| 2025-08-19 | P00008 | Administrative change | $0 | PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES |
| 2025-01-07 | P00007 | Option exercised | $629.8K | PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES |
| 2024-09-04 | P00006 | Option exercised | $442.6K | PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES |
| 2024-07-15 | P00005 | Supplemental agreement (work within scope) | $720.4K | PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES |
| 2024-01-17 | P00004 | Supplemental agreement (work within scope) | $6.13M | PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES |
| 2023-11-08 | P00003 | Supplemental agreement (work within scope) | $597.0K | PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES |
| 2023-06-20 | P00002 | Supplemental agreement (work within scope) | $2.04M | PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY TOXICOLOGY STUDIES |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-28). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗